Formulation of Nanostructured Lipid Carriers(NLCs) of  20(S)-Protopanaxadiol(PPD) by Box-Behnken design by 김민환
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 
















Nanostructured Lipid Carriers(NLCs) of
20(S)-Protopanaxadiol(PPD)
by Box-Behnken Design
지도교수 김 대 덕







위 원 장 (인)









Department of Pharmaceutical Sciences
The Graduate School
Seoul National University
20(S)-Protopanaxadiol (PPD) is a deglycosylated metabolite of ginseng 
saponins like Compound K and Rb1. It was reported that PPD has a better anti-
wrinkle effect than the other glycon forms of PPD including 20-O-β-D-
glucopyranosyl-20(S)-protopanaxadiol (GPPD) and ginsenoside Rb1 in a human 
skin equivalent model and human keratinocytes (HaCaT). Despite its good anti-
wrinkle effect in cell models, PPD has a low aqueous solubility because of its
aglycon state and large molecular weight. Thus, it is expected be difficult to
penetrate the stratum corneum (SC) layer which is the rate limiting step of topical 
delivery. The purpose of this study was to optimize nanostructured lipid carrier
II
(NLC) of PPD by Box-Behnken Design and to evaluate the deposition of PPD in
Strat-M™, a model human skin. Drug amount (X1), volume of oil (X2) and 
surfactant amount (X3) were set as independent variables, while particle size (Y1), 
polydispersity index (PDI) (Y2) and entrapment efficiency (EE) (Y3) were set as 
dependent factors. After NLC was prepared based on the optimized formulation, its 
particle size, PDI and EE were actually measured. Difference between the 
predicted and the observed values was less than 5%, indicating the validity of the 
optimization. X-ray diffraction (XRD) indicates that PPD encapsulated in NLC 
formulation is in amorphous state. In vitro deposition of PPD after 3 h and 6 h after 
applying NLC on the Strat-M® artificial membrane was significantly higher than 
that of PPD suspension and oil solution. Thus, it can be concluded that the 
formulation of NLC was successfully optimized for the topical delivery of PPD.
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1. Introduction
Ginsenoside is one of the principal active components among the 
extracted compounds of Panax ginseng. One type of the ginsenosides is 
dammarane-type and it can be divided into protopanaxadiol (PPD) or 
protopanxatriol (PPT) types [1]. Because of its various effects like anti-cancer, 
anti- fatigue and whitening effect, many types of ginsenosides are widely used in 
Korea and China as a traditional herb and cosmetics. Nowadays algycon form of 
the ginsenosides has given attention to reserchers. 20(S)-Protopanaxadiol (PPD)
(Fig. 1) is a one of the ginsenosides which is a deglycosylated metabolite of 
ginseng saponins like compound K and Rb1 from the ginseng. PPD has a lot of 
pharmacological potentials like anti-depressant, anti-inflammatory and colon 
cancer [2-4]. Recently a study elucidated that PPD has a better anti-wrinkle effect 
than other glycon form of PPD including 20-O-β-D-glucopyranosyl-20(S)-
protopanaxadiol (GPPD) and ginsenoside Rb1 in a human skin equivalent model 
and human keratinocytes (HaCaT). MMP-1 is one of the key factor to attenuate the 
collagen degradation, so that anti-wrinkle can be represented for preventing 
photoaging. It shows that PPD has a better suppressing UV-induced MMP-1 
expression than GPPD and ginsenoside Rb1 [5]. There are few researchers of PPD 
in topical delivery. Inspite of its good efficacy on cell model, PPD has a low 
solubility in water because of the aglycon form and large molecular weight, so that 
it is hard to penetrate the stratum corneum(SC) which is the rate-limiting step of 
topical delivery. 
Colloidal systems have obtained popularity as a promising topical drug delivery
２
carrier. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) 
are developed to deliver lipophilic drugs [6]. The SLN were developed by 
substituting solid lipid for the liquid lipid(oil) which is inside of emulsions. 
Because of the drug mobility compared to liquid lipid, the replacement of oil with 
solid lipid is a very attractive to overcome the drawback of traditional formulation 
like emulsion. And NLC is composed of mixture of solid lipid and liquid lipid to 
overcome the problems associated with SLNs, such as low drug loading, drug 
expulsion during storage. Putting oil into the solid lipid makes polymorphic 
transition, so that it makes higher loading and controlled drug release [7]. 
Because of NLC having its unique lipid matrix for improving efficacy, lipid 
colloidal systems are used for many administration routes of the active compounds, 
like topical application [8]. Advantages of NLC over conventional topical drug 
delivery systems like liposomes and emulsions are skin occlusion, sustain drug or 
cosmetic release, increase of skin hydration, drug targeting [9] and potentials of 
UV blocking effects [10]. Cosmetically active compound should locate in the skin 
and should not permeation to minimize the systemic effects. For example, 
prednicarbate which is one of the topical corticosteroid drug retains more in the 
upper site of skin compared to an emulsion-based formulation [11].
To optimize formulation, there is a traditional approach called one factor at a time
(OFAT). This approach is difficult, time consuming and hard to know the 
interaction effect between the factors. Recently, many statistical experimental 
designs are used in optimizing a formulation with less experiment and estimating 
３
the relative significance among variables [12]. Statistical experimental design like 
Response Surface Methodology (RSM) has been revealed that it can be efficient to 
estimate the relationship between independent and dependent factors in a
formulation when interactions among variable are complicated. Several studies 
have shown that RSM is useful for optimizing formulation in many sorts of drug 
delivery systems including lipid nanoparticles. There are various types of RSM 
which is available for statistical optimization: Central Composite Design (CCD), 
Box-Behnken Design (BBD) and D-optimal designs [13]. In Box-Behnken Design 
which has a 3-factor experimental design, three levels of the factors are located at 
the midpoints and the edges of the process space. This design can make less 
experimental runs and time. For this reason, BBD is considered a cost- and labor-
effective approach than traditional optimizing processes of formulation. In this 
study, one of the RSM design, BBD, is used for optimizing the lipid formulation.
In recent years, there are many interests in finding alternative of animal 
experiment. Strat-M™ was recently launched and is now commercially available as 
a skin-mimic artificial membrane. This membrane is composed of three layers of 
polyester sulfone making similar morphology to human skin. The thickness of each 
layer increased from the top of the membrane [14]. There are several researches
that Strat-M™ have a possibility of alternative membrane for estimating skin 
permeation so that the membrane can be used as an alternative membrane model 
for human skin experiments. But there are not much researches of estimating skin 
deposition test. One article shows that in-vitro deposition of PPD between hairless 
４
mouse and Strat-M™ membrane had been investigated. Thus Strat-M™ has a 
potential to be an alternative of hairless mouse skin to check the deposition amount 
of PPD. The purpose of this study was to investigate the potential of applying 
topical delivery of PPD using NLC formulation. The PPD-loaded NLC
formulations were prepared and analyzed with regard to in vitro particle-size 
distribution, encapsulation efficiency, morphology, and XRD data. Then, the in 
vitro deposition properties were carried out using Strat-M™ membranes as an 
alternative of hairless skin.
５
2. Materials and Methods
2.1. Materials
20(S)-Protopanaxadiol (PPD) (purity>98.0%) was obtained from Xian 
Plant Bio-Engineering Co.,Ltd. (Shaan xi, China). Labrafac CC, Lauoroglycol CC, 
were obtained from Gattefosse Co. (Saint Priest, Cedex, France). Capmul MCM 
EP was obtained from ARITEC co. (Columbus, OH, USA). Miglyol 812 N was 
gifted from OLEO chemicals (Witten, Germany). Poloxamer 188 was gifted from 
BASF Co. (Ludwigshafen, Germany). Tween 20, Tween 80, isopropyl myristate, 
limonene, polyethylene glycol 400 (PEG400) was purchased from Sigma-Aldrich 
Co. (St. Louis, MO, USA). Strat-M™ was purchased from Merck Millipore
(Billerica, MA, U.S.A.). HPLC grade acetonitrile, water and methanol were 
purchased from Thermo Fisher Scientific Co. (Pittsburgh, PA, USA).
2.2. HPLC analysis
To measure entrapment efficiency of PPD, high-performance liquid 
chromatography (HPLC)-UV system was used. Samples were injected into a 
reverse-phase C18 column (Kinetex C18; 250×4.6 mm2, 5μm; Phenomenex). 
HPLC-UV system was equipped with a pump (Waters 1515; Waters Company, 
６
Milford, Massachusetts), a UV/Vis detector (Waters 2487), and an automatic 
injector (Waters 717 plus). The mobile phase consisted of acetonitrile and DDW 
(5:95, v/v). The flow rate was 1.0 mL/min, and the detection wavelength and the 
injection volume were 210nm and 20 μL, respectively. The lower limit of 
quantitation (LLOQ) of PPD was 1 μg/mL.
The deposition amount of 20S-PPD in Strat-M™ was determined by LC-MS/MS 
analysis using an Agilent LC-MS/MS system (Agilent Technologies, Santa Clara, 
CA, USA) equipped with an Agilent Technologies 1260 Infinity HPLC system and 
Agilent Technologies 6430 Triple Quad LC-MS system. The analysis was achieved 
using a Hypersil BDS C18 column (50 mm 4.6 mm, 5mm; Thermo Fisher 
Scientific Co). The flow rate was 0.37 mL/min and the mobile phase consisted of 
93% acetonitrile and 7% water containing 0.2 formic acid (v/v). The volume of 
injection was 10 μl. PPD was determined in the multiple reaction-monitoring mode 
with positive electrospray ionization. The ESI parameters were set as follows: gas 
flow- 9 L/min, gas temperature - 120℃, capillary voltage - 6,000 V, nebulizer 
pressure - 25 psi. The MRM was used to monitor the m/z 461.4 → m/z 425.5 for 
PPD analysis. The collision energy, fragment voltage, cell accelerator voltage and 
retention time of PPD were 4 eV, 111 V, and 1 V, 1.09 min, respectively. All LC-
MS/MS data were carried out using the MassHunter Workstation Software 
Quantitative Analysis (vB.05.00; Agilent Technologies). Stock solution was made 
with methanol and the standard curve samples were diluted with methanol from the 
stock solution. The response of the detector was linear in the concentration range 
and the mean correlation coefficient ( ) for the calibration curve was more than 
７
0.999. The lower limit of quantitation (LLOQ) of PPD was 2 ng/mL.
2.3. Selecting liquid lipid and surfactant
The solubility of PPD in various oil and surfactant was analyzed by 
putting an excessive amount of PPD into a 2.0 ml tube containing 1mL of each 
vehicle. The vortex shaker (Vortex-Genie 2; Scientific Industries, Inc., Bohemia, 
NY, USA) was carried out to make mixtures approach an equilibrium state at 50 
rpm at 25℃ for 72 h. After shaking the samples, they were centrifuged at 16,000g 
for 5 min, and the supernatant was filtered with 0.20-mm syringe filter to get rid of 
excess amount of PPD. Finally, the PPD was analyzed by HPLC-UV after 
appropriate dilution with methanol.
2.4. Preparation of APPD-loaded NLCs
PPD loaded NLC were prepared using previously described method with 
slight modification [15]. Briefly, solid lipid cetyl palmitate was melted above the 
10℃ higher than the melting point of solid lipid. Liquid lipid and PPD was 
dissolved in little amount of ethanol and put into melted phase. Distilled water 
containing mixtures of Tween 20 and poloxamer was added into lipid phase and 
ultrasonicated (sonic vibra cell) with amplitude 26% and pulse on 2 s; pulse off 3 s.
and then cooled in room temperature.
８
2.5. Experimental design
Box-Behnken design was used to statistically optimize the formulation 
and evaluate the main effects, interaction and quadratic effects of the formulation.
To optimize formulation, a Box-Behnken design of experiment (DOE) was created 
using Minitab® 17 software (Minitab, Inc.) by varying the independent variables of 
the design. The Box-Behnken design was selected because it requires minimum 
number of experiments than a CCD design in cases of three independent variables 
[16]. This design generate the set of points lying at the midpoint of each edge of a 
multidimensional cube and central point in triplicate. The non-linear quadratic 
model generated by the design is of the form:
Y = B1 + B2*X1 + B3*X2 + B4*X3 + B5*X1*X2 + B6* X2*X3 + B7*X1*X3 + 
B8*X1*X1 + B9*X2*X2 + B10*X3*X3 
The independent variables for optimization were the amount of drug (X1), volume 
of oil (X2), and amount of surfactant (X3), using the low, medium, and high level 
described in Table. 1. The obtained P-value less than 0.05 is considered statistically
significant. ANOVA was also applied to determine the significance of the model.
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2.5.1. Size and PDI
The particle size, polydispersity index (PDI), and intensity distribution of the 
formulation were analyzed in triplicate by an electrophoretic light-scattering (ELS) 
spectrophotometer (ELS 8000; Otsuka Electronics Co. Ltd., Tokyo, Japan). The 
samples were prepared in a quartz cuvette, and all measurements were carried out 
at 25℃.
2.5.2. Entrapment efficiency
Entrapment efficiency of PPD-NLC was calculated as described earlier with slight 
modification [17]. Briefly, NLC solution was obtained before the filtration process. 
The amount of entrapped PPD was measured by eliminating crystallized forms of 
PPD by filtration (Wattman syringe filter; nylon; 0.45 μm). The crude solution was
put into methanol to disrupt the formulation. And then it was centrifuged at 12000 
rpm for 15 min. Supernatant solution was analyzed using a HPLC system for 
calculating the amount of PPD in the NLC formulation. The encapsulation 
efficiency was calculated using following equation:






The morphology of 20(S)-PPD-loaded NLC was absorbed by an energy-
filtering transmission electron microscopy (TEM) (LIBRA 120, Carl Zeiss, 
Germany) at 80kV. A drop of PPD-NLC was loaded on a carbon-coated copper 
grid. And then it was negatively stained by 2% phosphotungstic acid. Stained 
copper grid was left to dry at room temperature.
2.5.4. Power X-ray diffraction (XRD)
To assess the crystallinity of drugs and other materials, powder X-ray 
diffraction was obtained (BRUCKER, German) using a Cu-Kα source. Samples 
were scanned between 2θ values (3 and 45°). Samples of the optimized NLC 
formulations, prepared with and without PPD and their components were run.
2.6. In vitro deposition test in Strat-M™ membrane
Measurement of in vitro deposition amount of PPD in Strat-M™ 
membrane was investigated by using previously described method with slight 
modification [18]. The Keshary-Chien diffusion cells have a 1.77     of surface 
area and the receptor chamber was filled with 0.5% tween 80 solution. Shiny side 
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of Strat-M™ membrane was mounted over the donor part of Keshary-Chien cells. 
NLC formulation and oil solution was filled into the donor compartment and was 
covered with parafilm to avoid the evaporation of samples. The Strat-M™ 
membrane was taken from the difusion cells at 3 hr and 6 hr after putting samples 
into the donor compartment and washed out with methanol 3 times. Then, 
membranes were put into the tube with acetone: MeOH (7:3,v/v) and shaken for 3
hr. The tube was put into the centrifuge for 5.0 min at 16000g. Then, an 1.0mL 
aliqout of the supernatant was evaporated by a nitrogen gas stream. It was
reconstituted with methanol. Amount of PPD was analyzed using LC-MS/MS as 
described above.
2.7. Statistical analysis
All experiments in this study were carried out at least three times, and the 
data were presented as mean ± standard deviation (SD). Statistical analyses were 
performed using the two-tailed t-test or analysis of variance (ANOVA) with post-
hoc test (IBM SPSS Statistics software, version 21.0; IBM Corp, Armonk, NY, 
USA), and p < 0.05 was considered significantly different. 
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3. Results and Discussion
3.1. Solubility test
Among oils tested, Miglyol 812 N showed a highest solubility in PPD.
Among surfactant tested, tween20 had a highest solubility in PPD (Table. 2).
3.2. Experimental design using Box-Behnken design
Box–Behnken design was applied to optimize the NLC formulation. 
Based on Preliminary experiments independent variables was set as follows; 
amount of drug (X1), volume of oil (X2), and amount of surfactant (X3). 
Dependent factor was set as follows; size (Y1), PDI (Y2) and EE (Y3). 15 
Experimental runs were generated using Box-Behnken Design. Table. 3 shows the 
15 experimental runs carried out for optimization. Moreover, 3D response surface 
graph was also plotted for the influence of variables on measured responses.
3.2.1 Effect on particle size
The size varied from 143.60 to 248.50. The effect of independent 
variables could be explained by the following quadratic equation.
１３
Size = 132.2 – 0.24*X1 + 1.139X2 – 60.5 X3 + 0.160*X1*X1 – 0.00137*X2*X2 
+ 25.99*X3*X3 – 0.0209*X1*X2 – 0.50*X1*X3 – 0.209*X2*X3
In case of particle size case, X2 and X3 has a statistically significant meaning 
(p<0.05). The most significant factor in particle size was amount of surfactant (X3) 
because of the value of the coefficient from the equation (Table. 6).
Figure. 2-1 shows the 2D-contour plots and 3D-response surface plots for particle 
size of NLCs. X2 factor showed the rising trend significantly on the NLC 
formulation size. This means that if the amount of lipid increase, particle size could 
increase. X3 factor showed a negative effect significantly on the particle size. This 
means that increasing volume of oil could increase the particle size and amount of 
surfactant could make particle size small [19]. Increasing the amount of surfactant 
can be attributed to reduction of the surface interfacial tension and lead to make 
smaller particle size.
3.2.2 Effect on PDI
In the case of PDI, PDI varied from 0.179 to 0.298. The effect and 
interactions of independent variables could be explained by the following quadratic
equation.
PDI = 0.2460 + 0.00648*X1 – 0.001270X2 + 0.0642 X3 + 0.000005*X2*X2 –
１４
0.00631*X3*X3 – 0.000013*X1*X2 – 0.00270*X1*X3 
In PDI, X1, X2 and X3 has a statistically significant meaning (p<0.05). The most 
significant factor in PDI was amount of surfactant (X3) because of the value of the
coefficient from the equation (Table. 6).
Figure 2-2. shows the 2D-contour plots and 3D-response surface plots for particle 
size of NLCs. X1 and X3 factor showed the rising trend significantly on PDI value. 
This means that if the amount of drug and surfactant increase, PDI could increase. 
X2 factor showed a negative effect significantly on PDI value. This means that 
increasing volume of oil could make PDI small. These effect can be explained that 
higher concentration of surfactant, drug in nanoparticle may promote aggregation 
due to their adhesive feature. Increasing amount of oil can decrease the PDI value.
3.2.3 Effect on EE
In the case of EE, EE varied from 40.45 to 84.45. The effect and interactions 
of independent variables could be explained by the following quadratic equation.
EE = 58.8 – 4.468*X1 + 0.641*X2 + 5.96*X3 – 0.003449*X2*X2 – 2.07*X3*X3 
+ 0.01503*X1*X2 + 0.878*X1*X3 
In EE, X1, X2 and X3 has a statistically significant meaning (p<0.05). The most 
significant factor in PDI was amount of surfactant (X3) because of the value of the 
１５
coefficient from the equation (Table. 6).
Figure 2-3 shows the 2D-contour plots and 3D-response surface plots for EE of 
NLCs. X1 factor showed the decreasing trend significantly on the NLC EE. This 
means that if the amount of PPD increase, EE could decrease. X2 factor showed a 
positive effect significantly on the EE. This means that increasing volume of oil 
could increase the EE. X3 factor shows a positive effect on EE. This means that 
increasing surfactant make EE higher. This effect can be explained that increasing 
oil and surfactant might increase PPD concentration and inner matrix space 
because of the imperfections of inner phase of the NLC formulation [20].
3.2.4 optimization and validation
The formulation was optimized on these criteria: minimum particle size, make 
PDI closer to 0.250, and maximum EE (Table. 4). Optimized formulation was 
made with composition of 5 mg of PPD, 82.3 μl of oil and 1.05% (v/v) of 
surfactant. This formulation was analyzed to check the validity of the optimization. 
Predicted value of the optimized formulation was found to be 155.42 of particle 
size, 0.250 of PDI and 80.63 of EE, respectively. The optimized formulation 
showed 148.7 ± 1.53 of particle size, 0.257 ± 0.014 of PDI, and 78.20 3.11 of EE
(Table. 5). Observed data and predicted data presented a similar value, so that 
validity of optimization can be supported. 
3.3 Transmission electron microscopy (TEM)
Shape and size of the optimized formulation were checked by TEM. NLC 
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showed a circle or oval shape without aggregation. The diameter of the observed 
formulation from TEM images had a good agreement with the data from an 
electrophoretic light-scattering spectrophotometer.
3.4 X-ray diffraction study
Fig. 4. shows the XRD data of PPD, cetyl palmitate, poloxamer, physical 
mixture of PPD, cetyl palmitate and poloxamer, NLC formulation without PPD, 
NLC formulation with PPD. The crystalline peak of PPD was clearly shown in the 
physical mixture (PM), whereas peak of PPD was not shown in the NLCs 
formulation. Decreasing peak intensity of PPD might be a evidence of changing 
crystallinity of PPD in NLC formulation. It shows that PPD encapsulated in lipid 
nanoparticle is existed in an amorphous condition. Changing crystalline state of 
PPD to amorphous state present improved drug solubility. Intensity of PPD-NLC 
was stronger than that of blank NLC. This can be assumed that PPD makes the 
PPD-NLC more crystalline [21].
3.5 In-vitro deposition study in Strat-M™
Fig. 5. shows in vitro deposition of PPD at 3 hr and 6 hr in Strat-M™
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membranes after the application of suspension, oil solution or NLC formulation of 
PPD. Deposition amounts of PPD were NLC formulation > oil solution > 
suspension. The PPD deposition at 3 hr and 6 hr on the Strat-M™ membrane was 
higher in NLC formulation and oil solution than in suspension (p < 0.01). NLC 
formulation had a higher deposition amount in Strat-M™ membrane than oil 
solution of PPD (p < 0.01). Based on known mechanisms that explain the 
increasing deposition amount of NLCs on topical drug delivery, it can be suggested 
that the NLC formulation enhances the deposition amount of PPD through the 
mechanisms described below:
(1) From Fick’s law, the concentration gradient is one of the dependent factor of 
the permeation flux [22]. As the lipophilicity of the lipids like oil can encapsulate 
more PPD in the formulation, concentration gradient is made higher and deliver 
PPD through the stratum corneum (SC). It can be supposed that using oil can make 
topical delivery better [23]. And (2) The hydration of the skin by the formulation is 
due to the water loss reduction caused by occlusion [9]. Hydration via skin 
occlusion can increase hydration in the stratum corneum and influence 
percutaneous absorption [24]. And (3) The surfactants can act as a chemical 
enhancer by irritating the lipid layers of SC or increasing the solubility of the drug 
in the formulation. These factors were involved in increasing the concentration of 
PPD in the skin [25,26].
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4. Conclusion
In this study, PPD-loaded NLCs were optimized and developed by 3-
factor, 3-level Box-Behnken design by using in the Minitab software. Based on the 
data from the Box-Behnken design, the amount of surfactant and PPD and oil were 
important factors for their physical properties of PPD-loaded NLCs. XRD analysis 
shows that the PPD had entrapped efficiently in amorphous state in the NLCs. In 
addition, PPD-loaded NLCs might be further incorporated into a gel-like 
formulation, so that it can enhance skin contact with easy application [27].
Results suggested that PPD-loaded NLCs enhanced drug deposition in the Strat-
M™ membrane compared to oil solution and suspension. From this data, PPD 
loaded NLCs is a potential tool for topical delivery to suppress MMP-1 expression
than the control. Further studies could be focused on the evaluation of the efficacy
of the optimized formulation in clinical test.
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X1 = PPD amount (mg) 2 10
X2 = oil amount (μl) 0 100
X3 = Tween20 (%,v/v) 0 2
２５
Table 2. Solubility of PPD in various liquid lipids and surfactants.
Solubility of liquid 
lipid(mg/ml)
Miglyol 812 N 12.64 ± 1.38
Capmul MCM 10.60 ± 1.44
L.A.S 8.06 ± 1.59
Lauroglycol CC 6.87 ± 0.38
Labrafac CC 3.80 ± 0.82
Solubility of 
Surfactant(mg/ml)
Tween 20 5.37 ± 0.89
Tween 80 3.55 ± 0.64
Isopropyl myristate 2.53 ± 0.73
Limonene 1.54 ± 0.26
PEG 400 0.02 ± 0.01
Each value in the mean ± SD ( n=3)
２６
Table 3. Size (Y1), PDI (Y2), EE (Y3) of optimized PPD-NLC formulations.
Run
Independent variables Observed data
x1 x2 x3 Y1 Y2 Y3
1
-1 0 -1 232 ± 2.17 0.18 ± 0.037
70.28 ± 1.458
1 -1 0 151 ± 2.44 0.29 ± 0.008
39.79 ± 0.929
3
0 0 0 167± 3.01 0.250± 0.007
70.22 ± 2.417
4
0 0 0 165 ± 1.30 0.257 0.001
72.57 ± 1.200
5
1 0 1 153 ± 1.21 0.29 ± 0.009 75.41 ± 2.688
6
0 0 0 162± 2.19 0.252± 0.022 75.16 ± 0.543
7
0 1 -1 248 ± 2.30 0.22 ± 0.03 56.73 ± 1.356
8
0 1 1 180 ± 2.88 0.25 ± 0.013 77.30 ± 1.787
9
-1 1 0 190 ± 2.55 0.25 ± 0.004 76.46 ± 5.799
10
-1 0 1 148 ± 3.10 0.272± 0.012 81.22 ± 4.560
11
1 0 -1 247.23 ± 1.55 0.249 ± 0.010
46.87 ± 2.251
12
0 -1 -1 174.2 ± 1.21 0.262 ± 0.010
43.94 ± 1.522
13
-1 -1 0 144 ± 1.79 0.28 ± 0.001
74.47 ± 1.891
14
0 -1 1 147.2 ± 0.62 0.298 ± 0.013
68.64 ± 0.913
15
1 1 0 176.8 ± 1.35 0.250 ± 0.013
56.82 ± 0.529
２７
Table 4. Goal of the dependent factors.
Dependent factors Goals
Y1 = Particle size(nm) Minimize
Y2 = PDI 0.250
Y3 = Entrapment Efficiency Maximize
２８
Table 5. Comparision between the observed and predicted value of Y1, Y2, Y3 in
optimized formulation






















Each unit of X1, X2, X3 is mg, ul, and %(v/v)
２９
Table 6. Results of regression analysis for Y1, Y2, Y3
Parameter Size(Y1) PDI(Y2) EE(Y3)
Coefficient p-value Coefficient p-value Coefficient p-value
Intercept 132.2 0.000 0.2460 0.000 58.8 0.000
X1 -0.24 0.740 0.00648 0.041 -4.468 0.000
X1^X1 0.160 0.629 - - - -
X2 1.139 0.008 -0.001270 0.008 0.641 0.000
X2^X2 -0.00137 0.679 0.000005 0.118 -0.003449 0.005
X3 -60.5 0.008 0.0642 0.002 5.96 0.001
X3^X3 25.99 0.020 0.00631 0.414 -2.07 0.358
X1X2 -0.0209 0.515 0.000013 0.657 0.01503 0.106
X1X3 -0.50 0.753 0.00270 0.047 0.878 0.067
X2X3 -0.209 0.221 - - - -




Fig 1. Structure of (A) 20(S)-Protopanaxadiol and (B) Compound K
３１
Fig 2.1 2-D contour plots and 3D response surface plots for the effect of PPD
amount, volume of oil, and surfactant amount on particle size
３２
Fig 2.2 2-D contour plots and 3D response surface plots for the effect of PPD 
amount, volume of oil, and surfactant amount on PDI
３３
Fig 2.3 2-D contour plots and 3D response surface plots for the effect of PPD
amount, volume of 
oil, and surfactant 
amount on EE
３４
Fig 3. TEM images of NLC formulation.
３５
Fig 4. X-ray diffraction patterns of PPD, cetyl palmitae, poloxamer, physical 
mixture of PPD, cetyl plamitate, and poloxamer, NLC without PPD, NLC with 
PPD
３６
Fig 5. In-vitro deposition of PPD in Strat-M™ membrane at 3 hr and 6 hr after 
topical administration of optimized formulation
국문초록
20(S)-Protopanaxadiol(PPD)는 Compound K와 ginsenoside 
３７
Rb1에서 당이 떨어진 대사체로서, matrix metalloproteinase-1 
(MMP-1) 활성 감소에 의한 피부노화방지 작용을 가지고 있다. 활성
성분의 피부 흡수과정에서 각질층을 통과하는 것이 가장 중요한
단계인데, PPD는 물에 잘 녹지 않고 분자량이 크기 때문에 각질층을 잘
통과하지 못하여 피부 흡수가 잘 안 될 것으로 예측이 된다. 그러므로
Fick의 확산 법칙에 근거하여, PPD의 피부 흡수를 증가시키기 위해서는
이를 가용화 할 수 있는 제형 개발이 필요하다. Lipid nanoparticle의 한
종류인 Nanostructured Lipid Carrier(NLC)는 기존에 알려진
리포좀이나 에멀젼에 비해 여러 장점을 가지고 있는데, 피부수화효과, 
약물의 지속방출, 안정성 증가 등이 대표적이다. 본 연구의 목적은
반응표면법 중 하나인 Box-Behnken Design을 이용하여 지용성
물질인 PPD의 피부 흡수를 증가시키기 위한 최적의 NLC 조성을 얻는
것이다. PPD의 양(X1), 오일의 양(X2), 계면활성제의 양(X3)을 세
개의 변수로 설정하였고, 입자의 크기(Y1), polydispersity index (PDI) 
(Y2), 봉입율(Y3)을 바탕으로 최적화를 진행하였다. 최적 조성으로부터
얻은 예측 값과 실측 값을 비교함으로써 실제로 최적화가 되었는지를
확인 하였다. Y1, Y2, Y3 값 모두 예측 값과 실측 값의 차이가
5%이내인 것으로부터 최적의 조성이 잘 도출되었음을 확인하였다. 또한, 
X-ray diffraction (XRD)를 통하여 PPD가 NLC 제형에 무정형의
상태로 봉입되어있음을 알 수 있었다.  최적 조성의 NLC를 피부 대체
３８
인공막인 Strat-M™에 적용한 후 시간에 따른 PPD의 잔류량을
평가하였다. PPD를 함유한 suspension과 oil solution에 비해 최적화된
NLC 조성을 적용하였을 때, 3시간과 6시간 후의 PDD 잔류량이 모두
유의성 있게 높은 값을 나타내었다. 이를 통해, PPD의 피부 적용을 위한
최적의 NLC 조성이 Box-Behnken design을 통해 성공적으로
도출되었음을 알 수 있었다.  
주요어: Box-Behnken design, 20(S)-Protopanaxadiol, Nanostructured Lipid 
Carriers(NLCs), Strat-M™, topical delivery
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